Background: A large electronic database analysis was conducted in a community of 351,799 people, ages 20-70 years to determine the prevalence and clinical characteristics of severe asthma, according to 2014 international guidelines and healthcare utilization.
Methods: Severe asthmatics were grouped into controlled severe-asthma and uncontrolled severe-asthma and additional subgroups of uncontrolled severe asthma on the basis of medications dispensed. Non-asthmatic population at the same ages served as controls.
Results: A total of 19,991 (5.68%) were diagnosed as asthmatic, of which 4.65% had severe asthma. Of these, one-third was uncontrolled severe-asthma. Controlled severe-asthma group was similar to non-severe asthma and non-asthmatics in the rate of emergency room visits (21.5%, 22%, and 20%, respectively) and to all cause hospitalizations (7.4%, 7.4%, and 6.4%, respectively). Uncontrolled severe-asthmatics had significantly more hospitalizations (RR = 2.9) than controlled severe-asthmatics. Only 19.2% of uncontrolled-severe asthmatics had IgE testing and 3.6% were dispensed omalizumab.
Conclusions: The prevalence of severe asthma is slightly less than 5% of all asthmatics. Controlling severe asthma is crucial to reducing healthcare utilization. A simple electronic database analysis, based on dispensed medications, can help healthcare providers identify subgroups of uncontrolled severe asthmatics that require focused efforts.
Clinical Trial Registration: NCT01961258. Ethics Committee approval: 032/2013C.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rmed.2016.12.017 | DOI Listing |
Front Bioeng Biotechnol
December 2024
Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Lung diseases account for over four million premature deaths every year, and experts predict that this number will increase in the future. The top cause of death globally is diseases which include conditions like lung cancer asthma and COPD. Treating severe acute lung injury is a complex task because lungs struggle to heal themselves in the presence of swelling inflammation and scarring caused by damage, to the lung tissues.
View Article and Find Full Text PDFClin Exp Allergy
January 2025
Allergy Center, National Center for Child Health and Development, Tokyo, Japan.
Clin Transl Allergy
January 2025
Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
Background: Most patients with severe asthma are sensitized to at least one allergen. Whether local immunoglobulin E (IgE) in induced sputum reflects asthma control status has not been investigated.
Methods: Patients with asthma were classified as well controlled, partly controlled, and uncontrolled asthma (UCA) according to Global Initiative for Asthma 2022 guidelines.
Zhonghua Jie He He Hu Xi Za Zhi
January 2025
Department of Pulmonary and Critical Care Medicine, NHC Key Laboratory of Diagnosis & Treatment of COPD/Inner Mongolia Key Laboratory of Respiratory Diseases, Inner Mongolia People's Hospital, Hohhot010017, China.
Thunderstorm asthma refers to the acute exacerbation of asthma triggered by extreme weather events, which poses life-threatening risks due to severe asthma attacks and strained medical resources. Recent climate changes, including global warming, the greenhouse effect, and increased carbon emissions, have increased the levels of environmental allergens, contributing to a higher incidence of asthma and other allergic diseases. In addition, the increasing frequency of thunderstorms has exacerbated the impact of thunderstorm asthma.
View Article and Find Full Text PDFClin Ther
January 2025
Department of Internal Medicine, Chi Mei Medical Center, Chiali, Taiwan; Department of Nursing, Min-Hwei Junior College of Health Care Management, Tainan, Taiwan. Electronic address:
Anti-interleukin-5 (IL-5), anti-IL-5 receptor and anti-interleukin-4 (IL-4) have emerged as potential treatments for severe eosinophilic asthma, yet their role in treating chronic obstructive pulmonary disease (COPD) is unclear. A literature review was conducted up to May 31, 2024. Only randomized controlled trials (RCTs) assessing the clinical efficacy and adverse effects of biological treatment (anti-IL-5/ anti-IL-5 receptor /anti-IL-4) in COPD patients were included in this meta-analysis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!